Evidence map›Paper›PMID 33652129›Full record

Trial reportContemporary clinical trials2021

Adherence rates during a randomized controlled trial evaluating the use of blinded acetaminophen and ibuprofen in children with asthma.

William J Sheehan, Ian M Paul, David T Mauger, James N Moy, Stanley J Szefler, Daniel J Jackson, Anne M Fitzpatrick, Michael D Cabana, Ronina Covar, Rachel G Robison and 1 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 1 country.

William J SheehanBoston Children's Hospital, Division of Allergy and Immunology, Harvard Medical School, Boston, MA, United States of America; Children's National Hospital, Division of Allergy and Immunology, George Washington University School of Medicine and Health Sciences, Washington DC, United States of America.
Ian M PaulPenn State College of Medicine, Department of Pediatrics, Hershey, PA, United States of America.
David T MaugerPenn State College of Medicine, Department of Public Health Sciences, Hershey, PA, United States of America.
James N MoyStroger Hospital of Cook County, Department of Pediatrics, Rush University Medical Center, Chicago, IL, United States of America.
Stanley J SzeflerChildren's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States of America.
Daniel J JacksonUniversity of Wisconsin School of Medicine and Public Health, Section of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Madison, WI, United States of America.
Anne M FitzpatrickEmory University, Department of Pediatrics, Atlanta, GA, United States of America.
Michael D CabanaUniversity of California, San Francisco, Department of Pediatrics, San Francisco, CA, United States of America.
Ronina CovarNational Jewish Health, Department of Pediatrics, Denver, CO, United States of America.
Rachel G RobisonAnn and Robert H. Lurie Children's Hospital of Chicago, Division of Allergy and Immunology, Chicago, IL, United States of America.
Wanda PhipatanakulBoston Children's Hospital, Division of Allergy and Immunology, Harvard Medical School, Boston, MA, United States of America. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
University of Colorado Denver · USBoston Children's Hospital · USEmory University · USHarvard University · USJohn H. Stroger, Jr. Hospital of Cook County · USLurie Children's Hospital · USPenn State Milton S. Hershey Medical Center · USPennsylvania State University · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · US

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Data Coordinating Center for the NHLBI Asthma Network (AsthmaNet)U10HL098115 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAUGER, DAVID T. · 2009 to 2015
$57.6M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Controlling and preventing Asthma progression and Severity in Kids (CASK)U01AI126614 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2016 to 2023
$21.0M
AsthmaNet: Brigham and Women's Hospital & Children's Hospital BostonU10HL098102 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, PHIPATANAKUL, WANDA · 2009 to 2015
$5.5M
Clinical Centers for the NHLBI Asthma Network (AsthmaNet)U10HL098075 · NHLBI · NATIONAL JEWISH HEALTH · PI SZEFLER, STANLEY J., WECHSLER, MICHAEL E · 2009 to 2015
$5.1M
AsthmaNet: UW-Madison Clinical and Translational Research CenterU10HL098090 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI LEMANSKE, ROBERT F, SORKNESS, CHRISTINE ANNE · 2009 to 2015
$4.8M
UCSF AsthmaNet Clinical CenterU10HL098107 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CABANA, MICHAEL D, LAZARUS, STEPHEN C · 2009 to 2015
$4.8M
NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002548NHLBI NIH HHS U10 HL098075NHLBI NIH HHS U10 HL098090NHLBI NIH HHS U10 HL098096NHLBI NIH HHS U10 HL098098NHLBI NIH HHS U10 HL098102NHLBI NIH HHS U10 HL098103NHLBI NIH HHS U10 HL098107NHLBI NIH HHS U10 HL098112NHLBI NIH HHS U10 HL098115NHLBI NIH HHS U10 HL098177NIAID NIH HHS K23 AI104780NIAID NIH HHS K24 AI106822NIAID NIH HHS U01 AI126614
6 · The paper itself

Abstract

BACKGROUND/

aimsWhen conducting clinical trials comparing over-the-counter (OTC) medications, the wide availability of these treatments are a potential challenge to maintaining study integrity. We seek to describe adherence to a study protocol involving widely available OTC medications.

methodsTo prospectively evaluate associations between acetaminophen use and asthma in 300 children aged 1-5 years, we conducted a double blind, randomized, controlled trial where parents administered blinded forms of either acetaminophen or ibuprofen as needed to their children over a 48 week period. Written and verbal instructions encouraged the exclusive use of the blinded study medication and discouraged OTC use. Adherence was determined by evaluating the frequency of use of per-protocol blinded study medication compared to off-protocol use of OTC medications.

results4195 doses of acetaminophen or ibuprofen were received by children during the study which included 3664 doses (87.3%) of blinded study medication adhering to the protocol and 531 doses (12.7%) of OTC products deviating from the protocol with better adherence among those randomized to ibuprofen as compared to acetaminophen (89.5% vs. 85.5% of doses, p < 0.01). Individually, 227 participants (75.7%) remained fully adherent by not receiving any OTC medications. Pre-study preference for either acetaminophen or ibuprofen by the participants' families was not associated with differential rates of adherence to the blinded medication.

conclusionThis parallel study demonstrated greater than 85% of acetaminophen or ibuprofen doses were blinded study medications adhering to the protocol while less than 15% were OTC deviations from the protocol. This successfully implemented study design provides a template to comparatively evaluate these and other OTC medications.

Indexed as

AsthmaIbuprofenAcetaminophenChildDouble-Blind MethodHumansAcetaminophenIbuprofenAcetaminophenAsthmaChildrenIbuprofenRandomized controlled trial

Identifiers

PMID33652129
PMCPMC8180511
OpenAlexW3134352526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.